Close Menu

KRAS

The NGS assay is designed to help physicians to identify non-small cell lung cancer patients who may benefit from eight targeted therapies.

AmoyDx's kit is designed to detect hotspot mutations/fusions in nine genes to help guide treatment decisions for non-small cell lung cancer patients.

The assay can identify KRAS, NRAS, PIK3CA, BRAF, and EGFR gene mutations, as well as 19 gene rearrangements of the ALK, ROS1, RET, NTRK1, and MET genes from FFPE.

The test is designed to detect cancer-driver gene variants associated with certain targeted solid tumor therapies, and is validated as a companion diagnostic.

The group plans to use the assay for translational studies on metastasis and drug resistance initially and to develop a clinical version later on.

This Week in PNAS

In PNAS this week: genome-editing approach, analysis of KRAS-mutant cancers modeled in genetically engineered mice, and more.

The recent study highlights strengths and weaknesses of numerous platforms and may help end users choose the best assay for their circumstances.

UCSF will analyze Two Pore Guys' handheld nanopore device for its ability to detect a KRAS mutation from patient blood and urine samples.

The combination of the new test with Biocartis' existing KRAS assay offers customers a complete solution for testing metastatic colorectal cancers as reccomended by professional guidelines.

Can Almost See It

Newsweek reports that cancer researchers are cautiously optimistic that they will soon be able to target mutant Ras.

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.